Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma

Pathology Research and Practice

Volumn 210, Issue 1, 2014, Pages 35-39

  Soini, Y ^a   Eskelinen, M ^b   Juvonen, P ^b   Karja V ^a   Haapasaari, K M ^c   Saarela, A ^d   Karihtala, P ^d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cancer; Carcinoma; Oxidative; Pancreas; Sulfiredoxin

Indexed keywords

DJ 1 PROTEIN; OXIDOREDUCTASE; SULFIREDOXIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL PREDICTION; SURVIVAL RATE;

CANCER; CARCINOMA; OXIDATIVE; PANCREAS; SULFIREDOXIN;

ADENOCARCINOMA; AGED; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; ONCOGENE PROTEINS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891492275     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.10.001     Document Type: Article

References (35)

1. Itoh K., Mimura J., Yamamoto M. Discovery of the Negative Regulator of Nrf2, Keap1: a historical overview. Antioxid. Redox Signal. 2010, 13:1665-1678.
2. Hu R., Saw C.L., Yu R., Kong A.N. Regulation of Nrf2 signaling for cancer chemoprevention: antioxidant coupled with anti-inflammatory. Antioxid. Redox Signal. 2010, 13:1679-1698.
3. Villeneuve N.F., Lau A., Zhang D.D. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid. Redox Signal. 2010, 13:1699-1712.
4. Hayes J.D., McMahon M., Chowdhry S., et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox Signal. 2010, 13:1713-1748.
5. Zhang D.D. The Nrf2-Keap1-ARE signaling pathway: the regulation and dual. function of Nrf2 in cancer. Antioxid. Redox Signal. 2010, 13:1623-1626.
6. Satoh H., Moriguchi T., Taguchi K., et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 2010, 31:1833-1843.
7. Rhee S.G., Yang KS, Kang S.W., Woo H.A., et al. Controlled elimination of intracellular H(2)O(2): regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification. Antioxid. Redox Signal. 2005, 7:619-626.
8. Woo H.A., Jeong W., Chang T.S., et al. Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. J. Biol. Chem. 2005, 280:3125-3128.
9. Findlay V.J., Tapiero H., Townsend D.M., Sulfiredoxin: a potential therapeutic agent?. Biomed. Pharmacother. 2005, 59:374-379.
10. Lei K., Townsend D.M., Tew K.D. Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response. Oncogene 2008, 27:4877-4887.
11. Soriano F.X., Baxter P., Murray L.M., et al. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol. Cells 2009, 27:279-282.
12. Singh A., Ling G., Suhasini A.N., et al. Nrf2-dependent sulfiredoxin-1 expression protects against cigarette smoke-induced oxidative stress in lungs. Free Radic. Biol. Med. 2009, 46:376-386.
13. Wei Q., Jiang H., Matthews C.P., et al. Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies. Proc. Natl. Acad. Sci. USA 2008, 105:19738-19743.
14. Yokota T., Sugawara K., Ito K., et al. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem. Biophys. Res. Commun. 2003, 312:1342-1348.
15. Mullett S.J., Hamilton R.L., Hinkle D.A. DJ-1 immunoreactivity in human brain astrocytes is dependent on infarct presence and infarct age. Neuropathology 2009, 29:125-131.
16. Sitaram R.T., Cairney C.J., Grabowski P., et al. The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma. Int. J. Cancer 2009, 125:783-790.
17. Liu H., Wang M., Li M., Wang J., et al. Expression and role of DJ-1 in leukemia. Biochem. Biophys. Res. Commun. 2008, 375:477-483.
18. Miyajima Y., Sato Y., Oka H., et al. Prognostic significance of nuclear DJ-1 expression in astrocytoma. Anticancer Res. 2010, 30:265-269.
19. Gu L., Cui T., Fan C., et al. Involvement of ERK1/2 signaling pathway in DJ-1-induced neuroprotection against oxidative stress. Biochem. Biophys. Res. Commun. 2009, 383:469-474.
20. Vasseur S., Afzal S., Tardivel-Lacombe J., et al. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc. Natl. Acad. Sci. USA 2009, 106:1111-1116.
21. Fan J., Ren H., Jia N., et al. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J. Biol. Chem. 2008, 283:4022-4030.
22. Krebiehl G., Ruckerbauer S., Burbulla L.F., et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One 2010, 5:e9367.
23. Clements C.M., McNally R.S., Conti B.J., et al. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl. Acad. Sci. USA 2006, 103:15091-15096.
24. Hamilton S.R., Aaltonen L.A. Pathology and Genetics of Tumours of the Gastrointestinal System. WHO International Classification of Tumours 2000, IARC Press, Lyon, France.
25. Mazur W., Lindholm P., Vuorinen K., Myllärniemi M., Salmenkivi K., Kinnula V.L. Cell-specific elevation of NRF2 and sulfiredoxin-1 as markers of oxidative stress in the lungs of idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. APMIS 2010, 118:703-712.
26. Singh A., Boldin-Adamsky S., Thimmulappa R.K., et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 2008, 68:7975-7984.
27. Solis L.M., Behrens C., Dong W., et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin. Cancer Res. 2010, 16:3743-3753.
28. Rangasamy T., Cho C.Y., Thimmulappa R.K., et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 2004, 114:1248-1259.
29. Reuter S., GuptaSC, Chaturvedi M.M., et al. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 2010, 49:1603-1616.
30. Stacy D.R., Ely K., Massion P.P., et al. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 2006, 28:813-818.
31. Zhu X.L., Wang Z.F., Lei W.B., et al. DJ-1: a novel independent prognostic marker for survival in glottic squamous cell carcinoma. Cancer Sci. 2010, 101:1320-1325.
32. Merikallio H., Pääkkö P., Kinnula V.L., et al. Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum. Pathol. 2012, 43:577-584.
33. He X.Y., Liu B.Y., Yao W.Y., et al. Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer. J. Dig. Dis. 2011, 12:131-137.
34. Chen Y., Kang M., Lu W., et al. DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer. J. Cancer Res. Clin. Oncol. 2010, 138:1463-1474.
35. Tian M., Cui Y.Z., Song G.H., et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as over expressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008, 8:241.